|
1
|
Ng T, Marx G, Littlewood T and Macdougall
I: Recombinant erythropoietin in clinical practice. Postgrad Med J.
79:367–376. 2003. View Article : Google Scholar
|
|
2
|
Leyland-Jones B: Breast cancer trial with
erythropoietin terminated unexpectedly. Lancet Oncol. 4:459–460.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Henke M, Laszig R, Rube C, et al:
Erythropoietin to treat head and neck cancer patients with anaemia
undergoing radiotherapy: randomised, double-blind,
placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar
|
|
4
|
Jelkmann W, Bohlius J, Hallek M and
Sytkowski AJ: The erythropoietin receptor in normal and cancer
tissues. Crit Rev Oncol Hematol. 67:39–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Glaspy JA: Erythropoiesis-stimulating
agents in oncology. J Natl Compr Cancer Netw. 6:565–575. 2008.
|
|
6
|
Glaspy J, Crawford J, Vansteenkiste J, et
al: Erythropoiesis-stimulating agents in oncology: a study-level
meta-analysis of survival and other safety outcomes. Br J Cancer.
102:301–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leyland-Jones B, Semiglazov V, Pawlicki M,
et al: Maintaining normal hemoglobin levels with epoetin alfa in
mainly nonanemic patients with metastatic breast cancer receiving
first-line chemotherapy: a survival study. J Clin Oncol.
23:5960–5972. 2005. View Article : Google Scholar
|
|
8
|
Temkin SM, Hellmann M, Serur E, Lee YC and
Abulafia O: Erythropoietin administration during primary treatment
for locally advanced cervical carcinoma is associated with poor
response to radiation. Int J Gynecol Cancer. 16:1855–1861. 2006.
View Article : Google Scholar
|
|
9
|
Wright JR, Ung YC, Julian JA, et al:
Randomized, double-blind, placebo-controlled trial of
erythropoietin in non-small-cell lung cancer with disease-related
anemia. J Clin Oncol. 25:1027–1032. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith RE Jr, Aapro MS, Ludwig H, et al:
Darbepoetin alpha for the treatment of anemia in patients with
active cancer not receiving chemotherapy or radiotherapy: results
of a phase III, multicenter, randomized, double-blind,
placebo-controlled study. J Clin Oncol. 26:1040–1050. 2008.
View Article : Google Scholar
|
|
11
|
Thomas G, Ali S, Hoebers FJ, et al: Phase
III trial to evaluate the efficacy of maintaining hemoglobin levels
above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without
erythropoietin in anemic patients receiving concurrent radiation
and cisplatin for cervical cancer. Gynecol Oncol. 108:317–325.
2008. View Article : Google Scholar
|
|
12
|
Lee YS, Vortmeyer AO, Lubensky IA, et al:
Coexpression of erythropoietin and erythropoietin receptor in von
Hippel-Lindau disease-associated renal cysts and renal cell
carcinoma. Clin Cancer Res. 11:1059–1064. 2005.PubMed/NCBI
|
|
13
|
Saintigny P, Besse B, Callard P, et al:
Erythropoietin and erythropoietin receptor coexpression is
associated with poor survival in stage I non-small cell lung
cancer. Clin Cancer Res. 13:4825–4831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai SY, Childs EE, Xi S, et al:
Erythropoietin-mediated activation of JAK-STAT signaling
contributes to cellular invasion in head and neck squamous cell
carcinoma. Oncogene. 24:4442–4449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arcasoy MO, Amin K, Vollmer RT, Jiang X,
Demark-Wahnefried W and Haroon ZA: Erythropoietin and
erythropoietin receptor expression in human prostate cancer. Mod
Pathol. 18:421–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong JY, Feldman L, Solar P, Szenajch J
and Sytkowski AJ: Characterization of erythropoietin receptor and
erythropoietin expression and function in human ovarian cancer
cells. Int J Cancer. 122:274–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Acs G, Acs P, Beckwith SM, et al:
Erythropoietin and erythropoietin receptor expression in human
cancer. Cancer Res. 61:3561–3565. 2001.PubMed/NCBI
|
|
18
|
Ellegala DB, Alden TD, Couture DE, Vance
ML, Maartens NF and Laws ER Jr: Anemia, testosterone, and pituitary
adenoma in men. J Neurosurg. 98:974–977. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimon I, Benbassat C, Tzvetov G and
Grozinsky-Glasberg S: Anemia in a cohort of men with
macroprolactinomas: increase in hemoglobin levels follows prolactin
suppression. Pituitary. 14:11–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aron DC, Tyrrell JB and Wilson CB:
Pituitary tumors. Current concepts in diagnosis and management.
West J Med. 162:340–352. 1995.PubMed/NCBI
|
|
21
|
Ribatti D: Erythropoietin and tumor
angiogenesis. Stem Cells Dev. 19:1–4. 2010. View Article : Google Scholar
|
|
22
|
Funamoto M, Fujio Y, Kunisada K, et al:
Signal transducer and activator of transcription 3 is required for
glycoprotein 130-mediated induction of vascular endothelial growth
factor in cardiac myocytes. J Biol Chem. 275:10561–10566. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells From
clinic to bench - a critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
24
|
Hardee ME, Arcasoy MO, Blackwell KL,
Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer.
Clin Cancer Res. 12:332–339. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohyeldin A, Lu H, Dalgard C, et al:
Erythropoietin signaling promotes invasiveness of human head and
neck squamous cell carcinoma. Neoplasia. 7:537–543. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okazaki T, Ebihara S, Asada M, Yamanda S,
Niu K and Arai H: Erythropoietin promotes the growth of tumors
lacking its receptor and decreases survival of tumor-bearing mice
by enhancing angiogenesis. Neoplasia. 10:932–939. 2008.PubMed/NCBI
|
|
27
|
Ribatti D, Vacca A, Roccaro AM, Crivellato
E and Presta M: Erythropoietin as an angiogenic factor. Eur J Clin
Invest. 33:891–896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ribatti D, Poliani PL, Longo V, Mangieri
D, Nico B and Vacca A: Erythropoietin/erythropoietin receptor
system is involved in angiogenesis in human neuroblastoma.
Histopathology. 50:636–641. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Anagnostou A, Lee ES, Kessimian N,
Levinson R and Steiner M: Erythropoietin has a mitogenic and
positive chemotactic effect on endothelial cells. Proc Natl Acad
Sci USA. 87:5978–5982. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hardee ME, Cao Y, Fu P, et al:
Erythropoietin blockade inhibits the induction of tumor
angiogenesis and progression. PLoS One. 2:e5492007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Asaumi Y, Kagaya Y, Takeda M, et al:
Protective role of endogenous erythropoietin system in
nonhematopoietic cells against pressure overload-induced left
ventricular dysfunction in mice. Circulation. 115:2022–2032. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osugi T, Oshima Y, Fujio Y, et al:
Cardiac-specific activation of signal transducer and activator of
transcription 3 promotes vascular formation in the heart. J Biol
Chem. 277:6676–6681. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hilfiker-Kleiner D, Limbourg A and Drexler
H: STAT3-mediated activation of myocardial capillary growth. Trends
Cardiovasc Med. 15:152–157. 2005. View Article : Google Scholar : PubMed/NCBI
|
